Synthio Labs, a clinical-grade voice AI company, has raised $5 million in seed funding to build a voice-powered AI operating system tailored for the life sciences industry. The round was led by Elevation Capital, with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several strategic angel investors from the global healthcare and AI ecosystems.
What Synthio Labs Does
Synthio Labs is developing an AI Operating System that unifies three flagship products:
- Jarvis — a clinical-grade Voice AI copilot for pharmaceutical field teams.
- Ather — a multimodal AI engine that powers omnichannel engagement with physicians and patients.
- Simulation Studio — a high-fidelity insights platform that creates “digital twins” of clinicians and patients to inform strategy and research.
Together, these tools help life sciences organizations automate compliant conversations, capture structured intelligence at scale, and deliver consistent, human-quality experiences.
Why This Matters
Pharma companies spend more than $30 billion annually on engaging doctors and patients, yet much of their outreach remains manual, fragmented, and difficult to scale. Synthio Labs aims to change that by providing real-time, compliant voice AI that delivers accurate medical information on demand — helping reduce informational overload for clinicians and improving support for patients, especially in chronic care programs.
One of the company’s early deployments is particularly revealing: in a pilot, Synthio’s voice AI reached over 5,000 eczema patients in just 48 hours, managing onboarding, screening, and follow-up autonomously.
Leadership Team
Synthio Labs was founded by:
- Supreet Deshpande — Co-founder & CEO
- Rajashekar Vasantha — Co-founder & CTO
- Sahitya Sridhar — Co-founder & Chief Product Officer (CPO)
The founding team brings deep domain expertise across pharma strategy and AI engineering, with backgrounds in firms like McKinsey, ZS Associates, Amazon, and Audible.
What They’ll Do with the Funding
Using the $5M, Synthio Labs plans to:
- Expand its engineering and product teams
- Scale enterprise deployments across the U.S. and Europe
- Deepen partnerships with major global pharmaceutical companies
Vision & Impact
- Supreet Deshpande (CEO): “Beyond breakthrough medicines, the future of healthcare will depend on how we reach and support every clinician and patient who relies on them … At Synthio, we’re building the AI infrastructure that makes that possible — intelligently, compliantly, and at scale.”
- Rajashekar Vasantha (CTO): “We’re creating a strong technological base to enable real conversations — real, compliant conversations at scale.”
- Sahitya Sridhar (CPO): “We want every interaction between pharma and its customers to be smarter, faster, more meaningful … our mission is to bring consumer-grade experiences to life sciences.”
Why It’s Strategic
Synthio Labs is not just building a chatbot or a voice assistant — it’s building infrastructure for pharma engagement. By offering a unified, compliant, and intelligent voice layer, they could redefine how pharmaceutical companies connect with clinicians and patients globally. As AI becomes more integral to healthcare operations, platforms like Synthio could shape the next wave of innovation in life sciences.
